University of New Mexico
Department of Chemistry and Chemical Biology

Sylvie Pailloux

Sylvie Pailloux
Position: with Robert Paine
Email: spaillou@unm.edu
Phone: 505.277.0512
Fax: 505.277.2609
Office: Room 215

Education

  • Ph.D. Organic Chemistry–Medicinal Chemistry, 2003, University of Lille 2 France
  • Postdoctoral Fellow and Research Assistant Professor in Organic Chemistry–Inorganic Chemistry, 2004–present, UNM (Pr. R.T.Paine)

Research

Molecular Design, Synthesis and Characterization of heterocyclic compounds for Medicinal Chemistry and Inorganic Chemistry applications:

  • S.A.R in PPARs
  • Coordination studies of Lanthanides

Recent Publications

  1. J.Org.Chem 72 (24), 3741–3745, 2007: Sylvie Pailloux, Iris Binyamin, Lorraine M. Deck, Brian M. Rapko, Benjamin P. Hay, Eileen N. Duesler, Sung Joon Kim and Robert T. Paine "Oxidation Reactivity Channels for 2–(Pyridin–2–yl)–N,N–diphenylacetamides"
  2. Inorg. Chem 45 (9), 3741–3745, 2006 : X. Gan, B.M. Rapko, J. Fox, I. Binyamin, S. Pailloux, E.M. Duesler and R.T. Paine "A Three Dimensional Framework Structure Constructed from 2–(Pyridyl N–oxide) Ethylphosphonic Acid and Nd(III)"
  3. J. Heterocyclic Chem 44(1), 99–103, 2007: I. Binyamin, S. Pailloux, B.P. Hay, E.N. Duesler, B.M. Rapko and R.T. Paine "Synthesis of Propionamide Pyridine and Pyridine N–oxide Ligands"
  4. Inorg. Chem 45 (15), 5886–5892, 2006: I. Binyamin, S. Pailloux, E.N. Duesler, B.M. Rapko and R.T. Paine "Synthesis and Lanthanide Coordination Properties of New 2,6–Bis(N–t–Butylacetamido) Pyridine and 2,6–Bis(N–t–Butylacetamido) Pyridine N–oxide Ligands"
  5. Dalton Trans 3912–3917, 2006: X. Gan, I. Binyamin, S. Pailloux, E.N. Duesler and R.T. Paine "Formation of a Layered Framework Structure Based Upon 4–Methyl–2,6–Bis(methylphosphonic acid)Phenol"
  6. EP 04291901: Leclerc, V., Pailloux, S., Carato, P., Introvigne, C., Lebégue, N., Berthelot, P., Dacquet, C., Boutin, J.A., Caignard, D.H., Renard, P ; Dérivés d'oxime hétérocycliques, leur procédé de préparation et leur utilisation dans le traitement du diabéte de type II.